Monheit Gary D, Dreher Frank
Total Skin & Beauty Dermatology Center, Birmingham, AL, USA.
J Drugs Dermatol. 2013 Mar;12(3):270-4.
The safety and efficacy of a novel skin-lightening cream (SLC) with 4% hydroquinone (HQ), which additionally contains 4 skin-brightening actives, was compared with a triple combination cream (TCC) with 4% HQ, 0.05% tretinoin, and 0.01% fluocinolone acetonide for the treatment of melasma under measures of sun protection. The study was a randomized, investigator-blinded, split-face study including 20 Caucasian females with at least mild epidermal or mixed melasma. Evaluations were made before treatment, after 4 and 8 weeks, and after 12 weeks at the end of the once-daily treatment period with the creams. The evaluations included the investigator's tolerability assessments, the Investigator's Global Assessment, the Melasma Area and Severity Index (MASI), and a participant questionnaire. Under the conditions of the present study, the SLC was comparable in both efficacy and tolerability with the well-established TCC treatment for facial melasma. The MASI reduction became significant for both creams after 4 weeks and reached -77% for SLC and -79% for TCC cream after 12 weeks of once-daily use under measures of sun protection. None of the subjects discontinued treatment because of an intolerability or adverse event. About one-third of the subjects experienced at least one local intolerability (eg, erythema, dryness, or peeling) with both creams over the entire study period, while the remaining subjects did not experience any intolerabilities.
一种含4%氢醌（HQ）且额外含有4种亮肤活性成分的新型美白面霜（SLC），在防晒措施下，与含4% HQ、0.05%维甲酸和0.01%醋酸氟轻松的三联复方乳膏（TCC）用于治疗黄褐斑的安全性和有效性进行了比较。该研究是一项随机、研究者盲法、半脸对照研究，纳入了20名患有至少轻度表皮型或混合型黄褐斑的白人女性。在使用这些面霜进行每日一次的治疗期结束前，分别于治疗前、4周、8周和12周进行评估。评估内容包括研究者的耐受性评估、研究者整体评估、黄褐斑面积和严重程度指数（MASI）以及一份受试者问卷。在本研究条件下，SLC在治疗面部黄褐斑的疗效和耐受性方面与成熟的TCC治疗相当。在防晒措施下，每日一次使用12周后，两种面霜的MASI降低在4周后均变得显著，SLC达到-77%，TCC乳膏达到-79%。没有受试者因不耐受或不良事件而停止治疗。在整个研究期间，约三分之一的受试者使用两种面霜时至少经历过一次局部不耐受（如红斑、干燥或脱皮），而其余受试者未出现任何不耐受情况。
